Abatacept Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Abatacept Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
243
Registered trials
430
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Abatacept can convert its Fc fusion protein profile and CD80 x CD86 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Abatacept (query alias: abatacept) |
|---|---|
| Modality / target | Fc fusion protein; CD80 x CD86; CD80 modulators, CD86 modulators |
| Highest global status | Approved |
| Originator | Bristol Myers Squibb Co. |
| Active developers | Baker Heart & Diabetes Institute, Bristol Myers Squibb Co., Bristol-Myers Squibb Pharma EEIG |
The MCP disease footprint includes Acute Graft Versus Host Disease, Juvenile Idiopathic Arthritis, Arthritis, Psoriatic. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07366801 | Phase 2/3 | Recruiting | 64 | Feasibility- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 |
| NCT07616154 | Phase 2 | Not yet recruiting | 45 | GVHD-free and rejection free survival (GRFS) |
| NCT07599176 | Phase 1/2 | Recruiting | 90 | Donor myeloid chimerism |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
OPTIMIZING BIOLOGIC THERAPY BEYOND TNF INHIBITION: COMPARATIVE EFFICACY AND PERSISTENCE IN REFRACTORY RHEUMATOID ARTHRITIS
Not Applicable; n=72000; evaluation: Positive. Reported fields: ACR20: OR = 3.3, P-Value = < 0.05; ACR20: OR = 3.3, P-Value = < 0.05; ACR20: OR = 3.3, P-Value = < 0.05
EFFECT OF NINTEDANIB ASSOCIATED WITH ABATACEPT IN RHEUMATOID ARTHRITIS–ASSOCIATED INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 526 PATIENTS
Not Applicable; n=526; evaluation: Positive. Reported fields: UIP pattern = 48.0 %
EARLY CLINICAL AND SEROLOGICAL EFFECTS OF ABATACEPT-DARATUMUMAB COMBINATION THERAPY IN INDIVIDUALS WITH ACTIVE AND ACPA-POSITIVE RHEUMATOID ARTHRITIS: PHASE I RESULTS OF THE CURACTA TRIAL
Phase 1/2; n=3; evaluation: Positive. Reported fields: AE = Most AEs were mild or moderate. All patients experienced transient non-severe symptoms indicative of systemic infusion-related reactions (IRR; e.g. erythema, hyperhidrosis), and one patient experienced local IRR. One patient had transient grade 4 neutropenia with leukopenia, which resolved without intervention. Total IgG levels decreased in all patients, and one patient received immunoglobulin replacement therapy due to IgG levels below 4g/l (week 24). No severe infections occurred.
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Abatacept addresses Acute Graft Versus Host Disease, Juvenile Idiopathic Arthritis, Arthritis, Psoriatic. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Fc fusion protein—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2011-09-20 | Bristol-Myers Squibb and Ono Enter into Strategic Agreement for Anti-PD-1 Antibody, BMS-936558/ONO-4538, and ORENCIA® (abatacept) | Approved | Financial terms not disclosed |
| 2010-11-03 | Simcere Pharmaceutical Group and Bristol-Myers Squibb Company Enter Innovative Partnership to Develop Early-Stage Oncology Compound | Approved | Financial terms not disclosed |
| 2008-04-08 | Repligen Announces Settlement with Bristol-Myers Squibb in Orencia® Lawsuit | Not disclosed | US$5.0M upfront |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
